Search results for "Practice"

showing 10 items of 2812 documents

“Ultra-sensitive” cardiac troponins: Requirements for effective implementation in clinical practice

2018

The measurement of cardiac troponins, either cardiac troponin I or T, has become the culprit of clinical decision making in patients with suspected acute coronary syndrome (ACS), especially in those with non-ST elevation myocardial infarction (NSTEMI). The leading analytical mainstays of cardiac troponin immunoassays include the limit of blank (LoB), limit of detection (LoD), functional sensitivity, the 99th percentile of a healthy reference population, along with the percentage of “ostensibly healthy” subjects displaying measurable values 50% in the general healthy population. The very recent commercialization of methods with further improved analytical sensitivity (i.e., “ultra-sensitive”…

medicine.medical_specialtyAcute coronary syndromeCardiac troponinClinical BiochemistryClinical Chemistry TestsReview030204 cardiovascular system & hematologyCulpritacute coronary syndromecardiac troponin; myocardial infarction; acute coronary syndrome; diagnostics03 medical and health sciences0302 clinical medicineTroponin TLimit of DetectionInternal medicinecardiac troponinmedicinediagnosticsHumansIn patient030212 general & internal medicineMyocardial infarctionUltra sensitiveacute coronary syndrome; cardiac troponin; diagnostics; myocardial infarctionbusiness.industryHealthy populationBiochemistry (medical)Troponin Imedicine.diseaseClinical Practicemyocardial infarctionCardiologybusinessAlgorithmsBiochemia Medica
researchProduct

Acute Coronary Syndrome in the Older Patient

2021

Coronary artery disease is one of the leading causes of morbidity and mortality, and its prevalence increases with age. The growing number of older patients and their differential characteristics make its management a challenge in clinical practice. The aim of this review is to summarize the state-of-the-art in diagnosis and treatment of acute coronary syndromes in this subgroup of patients. This comprises peculiarities of ST-segment elevation myocardial infarction (STEMI) management, updated evidence of non-STEMI therapeutic strategies, individualization of antiplatelet treatment (weighting ischemic and hemorrhagic risks), as well as assessment of geriatric conditions and ethical issues in…

medicine.medical_specialtyAcute coronary syndromeInfarto del miocardio con elevación del STEnfermedad cardiovascularAncianoReviewCardiologíaMalalties coronàrieselderlyPersones gransacute coronary syndromeCoronary artery diseaseOlder patientsInfarto del miocardio sin elevación del STInternal medicineMedicineSíndrome coronario agudoMyocardial infarctioncardiovascular diseasesEthical issuesbusiness.industryRGeneral Medicinemedicine.diseaseClinical PracticeCoronary heart diseasemyocardial infarctionCardiologyMedicineOlder peoplebusinessJournal of Clinical Medicine
researchProduct

C-Reactive Protein in Acute Coronary Syndrome. Looking Back in Order to Move Forward

2006

Recent years have seen a spectacular rise in the importance of biomarkers in acute coronary syndrome (ACS). The most notable of these biomarkers is, without doubt, troponin. Its usefulness for diagnosis, decision making, and prognostic stratification have been fully validated, and its use in daily clinical practice is now widespread.1 It should be pointed out that the kinetics of troponin release were studied in detail for different types of ACS right from the outset. This approach has clearly laid a solid foundation which has contributed to the current popularity of this marker. However, it was soon evident that not all patients with ACS and elevated troponin had a very poor prognosis,2-6 …

medicine.medical_specialtyAcute coronary syndromebiologybusiness.industryC-reactive proteinGeneral MedicineDiseaseChest painmedicine.diseaseTroponinClinical PracticeInternal medicineDaily practicebiology.proteinCardiologyBiomarker (medicine)Medicinemedicine.symptombusinessRevista Española de Cardiología (English Edition)
researchProduct

Actualización en cardiopatía isquémica

2009

This article contains a review of the main developments reported in 2011 on the pathophysiology, prevention, prognosis and treatment of chronic coronary artery disease and acute coronary syndrome, with or without ST-segment elevation. It also discusses the recommendations of the latest clinical practice guidelines.

medicine.medical_specialtyAcute coronary syndromebusiness.industryMEDLINEmedicine.diseasePathophysiologyClinical PracticeCoronary artery diseaseInternal medicinemedicineCardiologyMyocardial infarctionMyocardial infarction diagnosisRisk assessmentbusinessCardiology and Cardiovascular MedicineRevista Española de Cardiología
researchProduct

First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors

2021

AbstractAlthough non-functioning pituitary tumors are frequent, diagnostic and therapeutic concepts are not well standardized. We here present the first German multidisciplinary guideline on this topic. The single most important message is to manage the patients by a multidisciplinary team (consisting at least of an endocrinologist, a neurosurgeon, and a (neuro-) radiologist). The initial diagnostic work-up comprises a detailed characterization of both biochemical (focusing on hormonal excess or deficiency states) and morphological aspects (with magnetic resonance imaging of the sellar region). An ophthalmological examination is only needed in presence of symptoms or large tumors affecting …

medicine.medical_specialtyAdenomaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedizin030209 endocrinology & metabolism03 medical and health sciencesTherapeutic approach0302 clinical medicineEndocrinologyGermanyInternal MedicinemedicineHumansPituitary NeoplasmsNeuroradiologyPatient Care Teammedicine.diagnostic_testbusiness.industryPituitary tumorsMagnetic resonance imagingGeneral MedicineGuidelinemedicine.diseaseMagnetic Resonance ImagingRadiation therapyPractice Guidelines as TopicRadiologyNeurosurgerybusiness030217 neurology & neurosurgeryExperimental and Clinical Endocrinology & Diabetes
researchProduct

World Health Organization guidelines for cancer pain: a reappraisal

2005

Pain is a prevalent symptom experienced by at least 30% ofpatients undergoing an oncological treatment for metastaticdisease and by more than 70% of advanced cancer patients[1]. In 1986 the World Health Organization [2] published a setof guidelines for cancer pain management based on the three-step analgesic ladder [2]. The main aim of WHO guidelienswas to legitimize the prescribing of strong opioids, arisingfrom evidence of poor management of cancer pain, due toreluctance of health care professionals, institutions, and gov-ernment to use opioids because of fears of addition, toleranceand illegal abuse.Its application is reported to achieve satisfactory pain reliefin up to 90% of patients w…

medicine.medical_specialtyAlternative medicinePain reliefPainWorld Health OrganizationWorld healthAdrenal Cortex HormonesNeoplasmsHealth caremedicineHumansIntensive care medicineHigh rateAnalgesicsMorphinebusiness.industryBreakthrough PainSmall sampleHematologytransdermal fentanylAnalgesics OpioidOncologyOpioidAnesthesiaPractice Guidelines as TopicbusinessCancer painmedicine.drugAnnals of Oncology
researchProduct

Morning and smooth 24-h ambulatory blood pressure control is not achieved in general practice: results from the SURGE observational study.

2013

BACKGROUND The aim of this large-scale, practice-based observational study [Survey with HBPM and ABPM Under Real clinical conditions in General practice to Evaluate BP control in the early morning (SURGE)] was to ascertain the degree of morning and 24-h ambulatory blood pressure (ABP) control in hypertensive patients. METHODS Hypertensive patients [with uncontrolled clinic blood pressure (BP) >140/90 mmHg at screening] from nine different countries were included. Ambulatory BP monitoring was performed over 24 h at 15-min intervals during the day and at 20-min intervals during the night. Assessments included morning (0600-1159 h) and daytime ABP control (BP < 135/85 mmHg), and 24-h ABP contr…

medicine.medical_specialtyAmbulatory blood pressuregenetic structuresPhysiologyGeneral PracticeBlood PressureLeft ventricular hypertrophyHydrochlorothiazideAmbulatory careDiabetes mellitusInternal medicineInternal MedicinemedicineAmbulatory CareHumansMorningbusiness.industryMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseambulatory blood pressure monitoring hydrochlorothiazide telmisartanBlood pressureEndocrinologyTelmisartanCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct

Management of the paediatric airway: new developments

2006

During the last 2 years, some interesting new devices have been made available to improve airway management in children and infants, and several studies have advanced our understanding concerning risks and benefits of the current practice in the field. Certain risk factors for airway related problems during anaesthesia in children having a cold have been identified, and new aspects of the controversy concerning the use of cuffed endotracheal tubes in children presented. Novel video-assisted systems have been introduced for the management of the difficult airway in paediatric patients, and new applications for well known devices have been suggested, such as the laryngeal mask airway serving …

medicine.medical_specialtyAnesthesiology and Pain Medicinebusiness.industryCurrent practicemedicine.medical_treatmentmedicineAirway managementRisks and benefitsrespiratory systemAirwayIntensive care medicinebusinessCurrent Opinion in Anaesthesiology
researchProduct

Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?

2012

As the population becomes more obese and the prevalence of diabetes and the metabolic syndrome increases, low-density lipoprotein-cholesterol (LDL-C) may lose its value as a sole predictor for cardiovascular risk among lipids. Combined dyslipidemia is typically characterized by elevations in LDL-C and triglyceride levels, often accompanied by decreased high-density lipoproteincholesterol (HDL-C) concentrations and increased levels of small, dense LDL. This common disorder results from overproduction of hepatically synthesized apolipoprotein B in very low-density lipoproteins. In the last few years most of the international scientific guidelines as well as several expert panels have confirme…

medicine.medical_specialtyApolipoprotein BPopulationCombined dyslipidemia cholesterol low-density lipoprotein-cholesterol small dense low-density lipoprotein high-density lipoprotein- cholesterol non-high-density lipoprotein-cholesterolchemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusDrug DiscoveryAnimalsHumansMedicineeducationTriglyceridesApolipoproteins BDyslipidemiasPharmacologyLdl cholesteroleducation.field_of_studybiologyTriglyceridebusiness.industryCholesterolCholesterol HDLCholesterol LDLAtherosclerosismedicine.diseaseEndocrinologychemistryCardiovascular DiseasesPractice Guidelines as Topicbiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent Pharmaceutical Design
researchProduct

How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL

2017

Background and aims: The maintenance of clinically recommended levels of low-density lipoprotein cholesterol (LDL-C) through a statin therapy is a gold standard in the management of patients with dyslipidaemia and cardiovascular disease (CVD). However, even when LDL-C levels are at or below clinically recommended target levels, residual cardiovascular (CV) risk still remains. Therefore, assessing lipoproteins beyond LDL-C in managing CV risk is imperative. Methods: A working group of clinical experts have assessed the role of lipoproteins other than LDL-C in identifying the CV risk in patients with dyslipidaemia and CVD and in the management of atherogenic dyslipidaemia associated with a nu…

medicine.medical_specialtyApolipoprotein BType 2 diabetes030204 cardiovascular system & hematologyRisk AssessmentTriglyceride03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHigh-density lipoprotein cholesterolRisk FactorsInternal medicinemedicineInternal MedicineHumans030212 general & internal medicineAtherogenic dyslipidaemiaHypolipidemic AgentsbiologyCholesterolbusiness.industryDisease Managementnutritional and metabolic diseasesGeneral MedicineLipoprotein(a)Cholesterol LDLmedicine.diseaseCardiovascular diseaseCardiovascular riskResidual riskNon-high-density lipoprotein cholesterolEndocrinologychemistryCardiovascular DiseasesPractice Guidelines as Topicbiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessRisk assessmentCardiology and Cardiovascular MedicineApolipoprotein BBiomarkersLipoproteinLipoprotein(a)
researchProduct